Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Bristol-Myers Squibb (NYSE: BMY) announced some interesting news last week about its promising lung cancer drug candidate. After analyzing early findings of a clinical trial featuring a combination of its two immuno-oncology drugs, Yervoy and Opdivo, Bristol-Myers found that the drug combo met its primary endpoint of improving life expectancy in lung cancer patients.